Breast-feeding reduces diarrheal and respiratory disease morbidity and mortality among infants in the developing world [1] , but the protection afforded by the breast milk of HIV-infected women is uncertain. Compared with formula feeding, breast-feeding reduced infant morbidity and mortality from diarrheal and re-ease [4] [5] [6] [7] . The cause of this excess morbidity and mortality remains unknown and may include biological factors (including differences in protection afforded by breast milk) or environmental and demographic factors. No published data have evaluated immunologic factors in the breast milk of HIV-infected women. Pathogen-specific antibodies in breast milk have been associated with decreased rates of associated illnesses in children [8] [9] [10] [11] and can be considered markers for immunologic integrity.
To evaluate the immunologic integrity of the breast milk of HIV-infected women, we compared infant morbidity and mortality among cohorts of HIV-infected and HIV-uninfected women, risk factors for infant morbidity among HIV-infected women, and breast milk immunologic profiles of HIV-infected and HIV-uninfected women in Botswana.
METHODS

Participants and Approval
The present study was conducted at 4 sites in Botswana-2 villages, 1 town, and 1 city. Two groups of women were included:
1
. HIV-infected women:
The HIV-infected breast-feeding women participated in a randomized clinical trial to prevent mother-to-child transmission (MTCT) of HIV in Botswana. Known as "the Mashi Study" (mashi means "milk" in Setswana), this trial completed enrollment of 1200 HIV-infected women in October 2003. The Mashi Study employed a factorial design to determine (a) whether single-dose nevirapine given to mothers and infants provides additional MTCT prevention in the setting of maternal and infant zidovudine and (b) whether prophylactic zidovudine given to breast-feeding infants for 6 months prevents breast-feeding MTCT [2, 12] . Therefore, 600 women randomized to breast-feed for 6 months were eligible for inclusion in this substudy of breast-feeding women. In October 2002, highly active antiretroviral therapy (HAART) became available through the Botswana Government Antiretroviral Treatment Program and was offered to women with either CD4 cell counts !200 cells/mm 3 or AIDS and to infected infants.
2. HIV-uninfected women: 150 women who tested negative for HIV were concurrently followed-up at the Mashi Study sites. At each site, the first woman seen each week who received a negative HIV test result at posttest counseling was offered enrollment in this cohort. Study visits, administration of questionnaires, and processing of breast milk samples occurred in a manner similar to that for women in the Mashi Study.
Breast-feeding women were counseled monthly to exclusively breast-feed. HIV-infected women were encouraged to wean infants from breast milk at 6 months and were provided formula and weaning foods. Chlorinated water from standpipes was available at study locations and was the predominant water source used by study participants. Infants were evaluated monthly for 6 months and at least every 3 months thereafter.
Informed consent was obtained from all participants; approval for the study was granted by human subjects committees in Botswana, at the Harvard School of Public Health, and at the Uiversity of Minnesota. The human experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this trial.
Study Design
There were 3 separate analyses in our study, as outlined below.
Morbidity and mortality rates by HIV status. We compared morbidity and mortality rates among infants of HIVinfected and HIV-uninfected women at 6 and 24 months. Data for mortality, hospitalizations, diarrhea, and respiratory illnesses as well as infant growth parameters were either collected in real time or assessed at scheduled visits.
Case-control study of risk factors for poor infant outcomes among HIV-infected women. We used a case-control design to study risk factors for poor infant outcomes, selecting from HIV-infected women in the breast-feeding arm of the Mashi Study. Case subjects were defined as mothers whose infant had significant diarrheal or respiratory illness during the first 6 months of life. The case definition included all mothers of children with either (1) documented pneumonia based on World Health Organization (WHO) criteria, (2) rotavirus or culture-confirmed bacterial diarrhea, (3) persistent diarrhea (у14 days), or (4) у2 months in which diarrhea was reported. Diarrhea was defined as у3 loose stools in a 24-h period representing a change from the infant's normal pattern. One control subject was matched to each case subject, by delivery date (within 30 days) and by clinical site. Control subjects were defined as mothers of infants with no pneumonia or diarrhea reported during the first 6 months of life. Expressed breast milk samples were collected at 2 weeks, 2 months, and 5 months postpartum. For each case-control pair, the breast milk sample from the collection point immediately before the case definition was met was used for analysis.
Breast milk immunologic profiles by HIV status. To evaluate differences in the immunologic integrity of breast milk from HIV-infected and HIV-uninfected women, we compared breast milk levels of total IgG, IgM, and IgA; innate immune factors; and pathogen-specific IgG and IgA recognizing representative respiratory (Streptococcus pneumoniae and Haemophilus influenzae) and enteric (Campylobacter jejuni and Helicobacter pylori) pathogens in HIV-infected women with samples from HIV-uninfected women. For HIV-infected women, immunologic testing was performed on 1 breast milk specimen (sampled as described above); for HIV-uninfected women, the sample collected at the 2-month postpartum visit was used.
Processing of Breast Milk Samples and Infant Diagnostics
Breast milk was stored at 4ЊC until being processed the same day. In the laboratory, the milk was centrifuged at 400 g for 20 min. The fat/lipid layer was discarded. The breast milk fluid (supernatant) was aspirated and aliquoted in 0.5-1.8-mL volumes into cryovials. Supernatant was stored at Ϫ70ЊC until being shipped for testing. Infant stool samples were transported in Cary-Blair transport medium on the day of collection to the Gaborone Private Hospital microbiology laboratory for bacterial culture and rotavirus latex agglutination testing (Slidex Rota-Kit 2; bioMérieux).
Maternal Serum, Plasma HIV-1 RNA Levels, and CD4 Cell Counts
For HIV-infected women, serum was collected between 30 and 34 weeks of pregnancy and stored at Ϫ70ЊC until being shipped for immunologic testing. HIV-1 RNA levels and CD4 cell counts were determined at delivery. HIV-1 RNA copy number in plasma was quantified using the automated standard (lower detection limit, 400 copies/mL) COBAS Amplicor/Ampli Prep HIV-1 Monitor Test (version 1.5; Roche Molecular Systems).
Immunologic Testing of Breast Milk
Innate factors. Levels of lactoferrin and lysozyme were measured by ELISA [13] . The detector anti-lysozyme secondary antibody (muramidase) was biotinylated with N-hydroxysuccinimide biotin (Sigma) at a 2:1 ratio. Secretory leukocyte protease inhibitor (SLPI) was measured in serial 1:2 dilutions by a commercial SLPI ELISA (R&D Systems) per the manufacturer's recommendations. The coefficients of variation for each assay were !10%.
Total immunoglobulins. Total immunoglobulin levels in serum were measured by commercial nephelometry. Total IgG, IgM, and IgA levels in breast milk were measured by ELISA with unlabeled and horseradish peroxidase-labeled affinity-purified goat anti-human IgA, IgM, or IgG (Jackson ImmunoResearch Laboratories) as the capture and detector antibodies, respectively [14] . Coefficients of variation for each assay were 9.2% (IgA), 13.6% (IgG), and 17% (IgM).
Pathogen-specific antibodies. Capsule-specific IgG and IgA reactive with the 23-valent pneumococcal vaccine were measured in microtiter plates (MaxiSorp; Nunc) by ELISA [14] [15] [16] . Samples and standards were preadsorbed overnight at 4ЊC with purified pneumococcal cell wall polysaccharide (4 mg/mL; Statens Serum Institut) and 23F capsular polysaccharide (2 ug/ mL; ATCC 6322). Detector antibodies were horseradish peroxidase-labeled affinity-purified goat anti-human IgG and IgA (Jackson ImmunoResearch Laboratories). The coefficients of variation were 13% and 22% for vaccine-specific IgA and IgG, respectively. By use of IgG and IgA ELISAs with comparable formats and reagents, antibodies to Helicobacter pylori were assessed with whole-cell antigens [17, 18] , and C. jejuni IgA and IgG were assessed with purified acid-washed major antigens from 3 strains of C. jejuni [19] . Haemophilus influenzae levels were assessed with polyribosyl ribitol phosphate (Connaught Labs) linked to tyramine hydrochloride (Sigma) [16] . Coefficients of variation for all Helicobacter pylori, C. jejuni, and Haemophilus influenzae assays were !15%.
Breast milk cytokines. Cell-free milk supernatants were simultaneously analyzed in duplicate for the presence of interleukin (IL)-2, IL-4, IL-8, IL-10, IL-12 (p70), interferon (IFN)-g, tumor necrosis factor-a, and monocyte chemoattractant protein (MCP)-1 analytes, using Biosource beads with a BioRad multiplex luminometer, in accordance with the manufacturer's recommendations. The limit of detection for analytes was 2 pg/ mL, except for IFN-g (4 pg/mL).
Statistical Analyses
Statistical analyses were performed using SAS (version 8.2; SAS Institute). Infant morbidity/mortality was estimated by the method of Kaplan and Meier. Infants not experiencing events were censored at the last clinic evaluation (maximum of 24 months). Differences between HIV-exposed infants and HIVunexposed infants were based on standardized differences between Kaplan-Meier estimates. Infant wasting by 6 and 24 months was calculated as the observed binomial proportion of babies who had a weight-for-height z score (adjusted for sex) 12 SDs below the mean for the National Center for Health Statistics/WHO 1977 reference population. Differences between groups were compared using Fisher's exact test.
Wilcoxon nonparametric tests were used to compare breast milk factors of HIV-infected and HIV-uninfected women. Spearman correlations were used to correlate factors in breast milk and serum and to correlate baseline CD4 cell counts and HIV-1 RNA levels with breast milk immunoglobulins. Univariate conditional logistic regression analysis was used to estimate associations between case and control subjects. All covariates with were included in multivariate conditional logistic P ! .2 regression modeling; those with few outcomes were removed to improve the final model and were added back independently to assess their significance. HIV-1 RNA levels in plasma were log 10 transformed for analyses. The case-control study was powered to have an 80% chance of detecting an odds ratio of 3.3 between matched case and control subjects for dichotomous variables, assuming an exposure rate of 30% among the matched control subjects.
RESULTS
Morbidity and mortality by HIV status.
Complete followup data were available for 54 HIV-infected infants, 534 HIVexposed uninfected infants, and 137 HIV-unexposed infants. Mortality was highest among HIV-infected infants, but it was ). At both time P p .08 points, there were also significantly more hospitalizations among the HIV-exposed infants. The median duration of breast-feeding was 5.8 months among HIV-infected women, compared with 9.0 months among HIV-uninfected women. The frequency of exclusive breast-feeding among HIV-infected women was 17.5% by 5 months [2] , compared with 9.5% by 5 months among HIVuninfected women ( ). A complete analysis of the risk P ! .001 factors associated with morbidity, mortality, and HIV infection in the Mashi Study will be presented elsewhere.
Case-control study among HIV-infected women. Among HIV-infected women in the Mashi Study cohort, 60 women whose infants had diarrhea or pneumonia (case subjects) were matched to 60 women whose infants were well (control subjects). One breast milk sample was evaluated for each woman, from the collection point immediately before the case subjects met the case definition-2 pairs (3.3%) at the birth visit, 24 pairs (40.0%) at 2 weeks, 30 pairs (50.0%) at 2 months, and 4 pairs (6.7%) at 5 months. Nine women received HAART during the first 6 months postpartum (4 cases and 5 control subjects).
We evaluated case subjects and matched control subjects for differences in the covariates listed in table 2. The absence of breast-feeding at the time the case subject (or matched case subject) met the case definition had the strongest univariate association with being a case subject ( ). Multivariate P ! .001 analysis was limited because of the small sample size but again identified the absence of breast-feeding ( ), not having P ! .001 a refrigerator in the home ( ), and low birth weight P ! .001 ( ) to be more likely in case than in control subjects. P p .018 No differences were noted between case and control subjects in either total breast milk IgA, IgG, or IgM levels; in pathogenspecific breast milk IgA or IgG levels; or in breast milk immunologic factors. The only cytokines detectable in the majority of breast milk samples were IL-8 and MCP-1, and no differences were detected. Seven infants were HIV infected (6 case and 1 control subject), and 2 received HAART (1 case and 1 control subject). Findings were similar when matched pairs that included a mother of an HIV-infected infant were excluded from the analyses. Neither maternal CD4 cell count nor plasma HIV-1 RNA level at delivery differed between case and control subjects, and neither variable correlated with total or specific breast milk immunoglobulin levels either including or excluding those women receiving HAART (data not shown). Delivery HIV-1 RNA level did not correlate with any breast milk factors.
Comparison of HIV-infected and HIV-uninfected breast milk. Because breast milk immunologic parameters did not differ between HIV-infected case and control subjects, we combined breast milk results available from the 120 HIV-infected women in the case-control study for comparison with a group of 45 breast milk samples collected at 2 months postpartum from HIV-uninfected women. Sufficient breast milk was available to perform immunologic comparisons for at least 100 HIVinfected samples and at least 40 HIV-uninfected samples for all comparisons. For the majority of comparisons, levels of innate and pathogen-specific immune factors were similar in the 2 groups (figure 1). Total IgG, IgM, and IgA levels were higher in the breast milk of HIV-infected women than in that of HIV-uninfected women ( , , and P ! .0001 P p .0002 P p , respectively), although IgA as a percentage of total im-.02 munoglobulins was lower (
). Haemophilus influenzae P p .0002 IgG (but not IgA) was higher in breast milk from HIV-infected women (
), but specific IgG and IgA levels for C. P p .0006 jejuni, Helicobacter pylori, and S. pneumoniae were similar among all women. SLPI levels were higher in HIV-infected women ( ). Because breast milk might have differed P p .0001 in composition over time, we also performed an analysis using only 2-month samples from HIV-infected and HIV-uninfected women. When the analysis was limited in this manner, the only difference in our findings was that total IgA level was no longer significantly different between groups.
DISCUSSION
We performed 3 analyses to evaluate the protection afforded by the breast milk of HIV-infected women. First, our epidemiologic comparison detected higher morbidity and mortality among HIV-exposed breast-fed infants, compared with that among a similar group of HIV-unexposed infants. Second, we found no correlation between infant illness and breast milk profiles among infants born to HIV-infected women. Finally, we found that levels of innate immune factors and pathogenspecific antibodies were generally comparable in the breast milk of HIV-infected and HIV-uninfected women. Taken together, these findings support previous concerns about high infant morbidity and mortality among HIV-exposed infants but also provide the first reported assurance that immunologic deficiencies in the breast milk of HIV-infected women are an unlikely cause for the observed increased in morbidity and mortality.
Our epidemiologic findings are consistent with previous studies comparing HIV-exposed and HIV-unexposed infants. Recent studies in Zimbabwe and Uganda have reported 2-4-fold higher mortality in large cohorts of HIV-exposed infants, compared with that in HIV-unexposed infants [5, 6] . These findings, and a meta-analysis of mortality among HIV-exposed infants [20] , highlight concerns about high infant mortality among HIV-exposed infants in the developing world. As access to antiretroviral interventions reduces the number of HIV-infected infants, excess mortality among uninfected infants must be viewed with concern by both MTCT prevention and childhood survival programs.
An important difference between the HIV-exposed and HIVunexposed infants in our study was the duration of breastfeeding, which was a median of 5.8 months in the HIV-exposed group (weaning was encouraged between 5 and 6 months) but 9 months in the HIV-unexposed group. Although this difference was less than anticipated (weaning occurs later in many African settings), it may have contributed to the difference in mortality rates. Exclusive breast-feeding was uncommon in both groups but lower in the HIV-uninfected cohort and was therefore unlikely to have biased the mortality results in favor of HIV-unexposed infants. The WHO recommends exclusive breast-feeding and early weaning for infants whose mothers are HIV infected [1] . However, our study shows high 6-and 24-month mortality among HIV-exposed infants in the setting of early weaning. It is unknown how findings might differ if wean-ing were to occur later. The optimal age for weaning HIVexposed infants may therefore require further study, balancing the risk of HIV transmission with the risk of infant mortality from childhood illnesses. This balance may also be affected by strategies that potentially reduce HIV transmission during breast-feeding, such as infant antiretroviral prophylaxis or maternal HAART.
Among HIV-infected women included in our case-control study, weaning from breast milk and the lack of a refrigerator in the home were most predictive of infant illness. Weaning is well described as a period of risk among infants in the developing world [21] [22] [23] , and our findings stress the importance of close follow-up and supportive care during this period. Reverse causality may have contributed to this finding (ill infants may not have been able to breast-feed), but the strength of the association and the consistency with the literature suggest that weaning itself was a risk. The lack of a refrigerator may indicate less safe storage of weaning foods or lower socioeconomic status. We analyzed our case-control study both including and excluding matched pairs for which an infant was HIV infected and found no significant differences. Although the case-control study did not identify maternal HIV-1 RNA level or CD4 cell count as risk factors for illness (perhaps because 9 women received HAART), these were associated with infant mortality in univariate (HIV-1 RNA level and CD4 cell count) (Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, unpublished data) and multivariate (HIV-1 RNA level) [2] analysis of mortality among breast-fed infants in the overall Mashi Study. Studies in Zimbabwe and Uganda also found an association between CD4 cell count and infant mortality [5] . However, our finding that baseline CD4 cell count and HIV-1 RNA level were not associated with breast milk immunologic profiles (even when women receiving HAART were excluded) suggests that breast milk protection is likely even with advanced maternal disease.
This is the first analysis we know of comparing breast milk immunologic profiles among HIV-infected and HIV-uninfected women, and we did not detect deficiencies in any specific immunoglobulin levels or in other immune factors in the HIVinfected women. The significance of higher total (but not specific) immunoglobulin levels in the breast milk of HIV-infected women is unclear but is consistent with the well-described hypergammaglobulinemia present in HIV-infected individuals [24, 25] . The lack of detectable deficiencies in the breast milk of HIV-infected women is reassuring, and our study supports the argument that exclusive breast-feeding for women at all stages of HIV infection may provide immunologic benefit to infants. These immunologic findings are also consistent with our overall findings from the Mashi Study, which demonstrated that breast-feeding was protective against diarrheal and respiratory illnesses compared with formula feeding [2] .
Our study has important limitations. These include few sampling points for breast milk and a sample size limited by the need for extensive laboratory testing. Although all women were drawn from the same population of antenatal clinic attendees, demographic data were limited for HIV-uninfected women. Exposed infants received prophylactic zidovudine for 6 months (which may have antibacterial properties [26, 27] ), whereas unexposed infants did not, and HIV-infected infants received cotrimoxazole. In addition, we did not measure immunoglobulin levels in infant serum, nor did we assess the qualitative state of breast milk immunoglobulins; it is possible that unmeasured or qualitative deficiencies may increase the risk of infant illness and death. However, our quantitative immunologic analysis was extensive and included a range of specific antibodies and known protective factors in breast milk. Finally, although misclassification of infant HIV status is a concern for infants who died in the Mashi Study and were classified as HIV uninfected, we do not believe this was likely because all infants in the breast-feeding arm who died and were classified as HIV uninfected had at least 1 negative HIV polymerase chain reaction (PCR) test (except for 1 infant who died of birth complications); all those who died at 11 month of age had at least 2 negative HIV PCR tests (more than half within 30 days of death); and all infant deaths were screened by blinded review before classification as HIV unrelated.
In summary, this is the first study we know of to explore whether specific factors in the breast milk of HIV-infected women predict illness in their infants and to compare the immunologic profiles of breast milk from HIV-infected and HIVuninfected women. Our findings demonstrate excess morbidity and mortality among HIV-exposed infants but do not suggest that this was caused by any identifiable breast milk deficiencies. Therefore, this study supports current recommendations for exclusive breast-feeding among HIV-infected women in regions in which formula feeding is unsafe or unfeasible but does not explain the high rate of mortality among HIV-exposed infants. This excess mortality may relate to early weaning, unmeasured immunologic deficiencies in breast milk, reduced immunologic protection conferred in utero, or social and environmental risk factors.
